Total Payments
$384,936
2024 Payments
$8,910
Companies
19
Transactions
485
Medicare Patients
438
Medicare Billing
$37,849
Payment Breakdown by Category
Other$231,228 (60.1%)
Consulting$112,460 (29.2%)
Travel$15,403 (4.0%)
Food & Beverage$11,588 (3.0%)
Education$7,350 (1.9%)
Research$6,908 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $222,928 | 80 | 57.9% |
| Consulting Fee | $112,460 | 32 | 29.2% |
| Travel and Lodging | $15,403 | 66 | 4.0% |
| Food and Beverage | $11,588 | 285 | 3.0% |
| Honoraria | $8,300 | 2 | 2.2% |
| Education | $7,350 | 11 | 1.9% |
| Unspecified | $6,908 | 9 | 1.8% |
Payments by Type
General
$378,028
476 transactions
Research
$6,908
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $204,956 | 190 | $0 (2023) |
| EMD Serono, Inc. | $46,513 | 87 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $26,783 | 22 | $0 (2022) |
| GENZYME CORPORATION | $22,183 | 48 | $0 (2024) |
| Horizon Therapeutics plc | $15,208 | 14 | $0 (2023) |
| Genentech USA, Inc. | $14,618 | 19 | $0 (2023) |
| Genentech, Inc. | $11,549 | 11 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $10,530 | 12 | $0 (2024) |
| Celgene Corporation | $9,934 | 21 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $8,456 | 13 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,910 | 20 | GENZYME CORPORATION ($4,659) |
| 2023 | $17,328 | 30 | Genentech USA, Inc. ($8,139) |
| 2022 | $64,906 | 51 | Biogen, Inc. ($36,773) |
| 2021 | $42,505 | 32 | Biogen, Inc. ($11,904) |
| 2020 | $43,419 | 50 | Biogen, Inc. ($28,099) |
| 2019 | $70,417 | 92 | Biogen, Inc. ($51,951) |
| 2018 | $75,236 | 116 | Biogen, Inc. ($43,052) |
| 2017 | $62,214 | 94 | Biogen, Inc. ($33,125) |
All Payment Transactions
485 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/14/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,055.80 | Research |
| Study: Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $555.53 | Research |
| Study: Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $911.14 | Research |
| Study: One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $707.93 | Research |
| Study: One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial • Category: Immunology | ||||||
| 06/03/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,485.00 | General |
| 06/03/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $140.02 | General |
| 06/03/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $34.17 | General |
| 05/30/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Neurology | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $3.83 | General |
| Category: Neurology | ||||||
| 05/23/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $59.24 | General |
| Category: Rare Disease | ||||||
| 04/26/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $133.34 | General |
| Category: Neurology | ||||||
| 04/17/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $28.59 | General |
| 04/16/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $132.19 | General |
| 04/16/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $126.36 | General |
| Category: Neurology | ||||||
| 04/15/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $42.81 | General |
| Category: Immunology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $378.00 | Research |
| Study: One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 03/21/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: Immunology | ||||||
| 02/29/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $44.66 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 01/11/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.67 | General |
| 12/01/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $15.65 | General |
| Category: Neurology | ||||||
| 11/08/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $85.34 | General |
| Category: Neurology | ||||||
| 11/01/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $14.82 | General |
| Category: Neurology | ||||||
| 10/12/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $21.59 | General |
| Category: Neurology | ||||||
| 10/11/2023 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $43.27 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, MULTICENTER STUDY TO ASSESS DISEASE ACTIVITY AND BIOMARKERS OF NEURONAL DAMAGE IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH OCRELIZUMAB | F. Hoffmann-La Roche AG | $1,828 | 2 |
| Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial | F. Hoffmann-La Roche AG | $1,611 | 2 |
| One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial | F. Hoffmann-La Roche AG | $1,289 | 2 |
| Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the Open-Label, Single-Arm, Multicenter, Phase IV CHIMES Trial | F. Hoffmann-La Roche AG | $799.08 | 1 |
| One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial | F. Hoffmann-La Roche AG | $707.93 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF H.P. ACTHAR? GEL IN THE SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | Mallinckrodt LLC | $672.91 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 94 | 112 | $23,535 | $7,591 |
| 2022 | 3 | 76 | 115 | $21,840 | $7,355 |
| 2021 | 5 | 129 | 171 | $33,248 | $11,938 |
| 2020 | 5 | 139 | 162 | $46,894 | $10,965 |
Total Patients
438
Total Services
560
Medicare Billing
$37,849
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 48 | 59 | $13,334 | $4,002 | 30.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $4,365 | $1,521 | 34.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 23 | $3,496 | $1,412 | 40.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 15 | $2,340 | $655.88 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 45 | 58 | $13,108 | $4,116 | 31.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 40 | $6,080 | $2,341 | 38.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 17 | $2,652 | $897.93 | 33.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 40 | 52 | $11,752 | $3,876 | 33.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 35 | 63 | $9,576 | $3,729 | 38.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $4,365 | $1,686 | 38.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 19 | 19 | $4,123 | $1,518 | 36.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 20 | 22 | $3,432 | $1,128 | 32.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 49 | 61 | $19,610 | $3,871 | 19.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 22 | 23 | $8,778 | $2,696 | 30.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 20 | 28 | $5,036 | $1,694 | 33.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 33 | 34 | $6,858 | $1,457 | 21.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 15 | 16 | $6,612 | $1,248 | 18.9% |
About Dr. Evanthia Bernitsas, MD
Dr. Evanthia Bernitsas, MD is a Neurology healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1528270808.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Evanthia Bernitsas, MD has received a total of $384,936 in payments from pharmaceutical and medical device companies, with $8,910 received in 2024. These payments were reported across 485 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($222,928).
As a Medicare-enrolled provider, Bernitsas has provided services to 438 Medicare beneficiaries, totaling 560 services with total Medicare billing of $37,849. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Detroit, MI
- Active Since 05/07/2007
- Last Updated 10/17/2016
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1528270808
Products in Payments
- TECFIDERA (Drug) $75,008
- TYSABRI (Biological) $43,554
- Rebif (Biological) $29,658
- VUMERITY (Drug) $20,175
- OCREVUS (Biological) $17,821
- Ponvory (Drug) $15,863
- UPLIZNA (Drug) $15,208
- PLEGRIDY (Biological) $15,094
- Ocrevus (Biological) $14,374
- LEMTRADA (Drug) $10,778
- COPAXONE (Drug) $8,357
- Mavenclad (Drug) $8,345
- Mavenclad (Biological) $7,303
- AUBAGIO (Drug) $6,640
- ZINBRYTA (Biological) $2,850
- Soliris (Drug) $2,550
- Ozanimod (Drug) $1,317
- Betaseron (Drug) $863.44
- Bafiertam (Drug) $800.00
- ACTHAR (Biological) $672.91
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Detroit
Bisena Bulica
Neurology — Payments: $640,257
Neurology $640,257
Talal Derani, M.d, M.D
Neurology — Payments: $274,940
Neurology $274,940
Andrew Russman, D.o, D.O
Neurology — Payments: $80,021
Neurology $80,021
Robert Lisak, Md, MD
Neurology — Payments: $78,692
Neurology $78,692
Brien Smith, M.d, M.D
Neurology — Payments: $51,998
Neurology $51,998
Panayiotis Varelas, M.d, M.D
Neurology — Payments: $49,998
Neurology $49,998